Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Subconjuctival injection of triamcinolone in the treatment of meibomian gland dysfunction

Search Title by author or title

Session Details

Session Title: Medical Cornea & Biomechanics

Session Date/Time: Sunday 23/09/2018 | 08:00-10:00

Paper Time: 08:06

Venue: Room A3, Podium 3

First Author: : S.Benchekroun MOROCCO

Co Author(s): :    R. El hadiri   R. El hachimi   O. Cherkaoui              

Abstract Details


The meibomian gland dysfunction (MGD) is a common condition seen in daily clinical practice and is the leading cause of evaporative dry eye. Its management is challenging for both patients and ophthalmologists due to the frustrating results that can be encountered after a long duration of chronic use of a constrained treatment. The objectif of this study is to assess the efficacy of subconjuctival injections of a long standing steroid (Triamcinolone) in cases of MGD in comparison to a conventional treatment.


Hopital des spécialités de Rabat, Mohammed V University; Morocco


We conducted a prospective, comparative and monocentric study between April and October 2017. We excluded patients with a history of previous ocular treatements or systemic anti-inflammatory drugs, patients presenting ocular hypertention or unilateral MGD. 40 patients having symptomatic bilateral MGD were randomized to two equal groups: one managed by eyelid hygiene heat compresses with oral doxycycline 100mg and artificial tears, the second group received one bilateral subconjunctival injection of 2mg of triamcinolone instead of doxycycline. The efficiency of the treatment was defined by a subjective impovement of visual comfort confirmed by at least two of three documented improved objective signs.


The mean age of the triamcilonone group was 67.14 years and 66.26 years for the non injected group. Sex ratio M/F was 1.22 for the injected eyes and 1.10 for conventionally treated patients. We noted functional improvement for 77.50% of the patients benefiting from the subconjuctival Triamcinolone injection. Among this sub-group, 80.64% had at least 2 objective clinical signs of improvement. Ocular hypertension occurred in 2 cases and was successfully managed by a monotherapy. Among the second group, only 47.50 % of the patients expressed functional amelioration and 84.21% of them respond to our definition of treatment efficacy. .


MGD is a complex and frequent disease. Its management must be adapted and optimized to obtain efficient results. In lack of emerging treatments in our context with frequently poor compliance for daily treatments, subconjunctival injection of triamcinolone represents a good and safe approach for our patients. According to our results, injected triamcinolone is associated with better efficacy and represents a safe and more comfortable alternative in the management of MGD. A largest study is needed for statistically significative results to corroborate the results of our experience.

Financial Disclosure:


Back to previous